サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405848

細胞膜透過ペプチドの市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント別予測、2024年～2030年

Cell Penetrating Peptide Market Size, Share & Trends Analysis Report By Type, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
細胞膜透過ペプチドの市場規模、シェア、動向分析レポート：タイプ別、用途別、最終用途別、地域別、セグメント別予測、2024年～2030年
出版日: 2023年12月12日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

細胞膜透過ペプチド市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の細胞膜透過ペプチド市場規模は2030年までに28億5,000万米ドルに達し、2024年から2030年までのCAGRは10.08%で拡大すると予測されています。

ターゲットを絞ったドラッグデリバリー手法に対する需要の高まりが、成長を後押しする主な要因です。化学修飾戦略やペプチド合成技術の技術的進歩や、正確な治療薬を導入するための研究開発活動の活発化が、細胞膜透過ペプチドの市場需要を高めています。

さらに、CPP技術に基づく新薬の承認が増加しており、調査期間中、主要プレーヤーに有利な機会を提供すると期待されています。例えば、2022年9月、Revance Therapeutics, Inc.は、重度から中等度のもみあげの一時的な改善のために細胞浸透技術に基づいて開発されたDAXXIFYの米国食品医薬品局の承認を取得しました。この承認が市場成長を後押しすると予測されます。

ペプチドの生産プロセスの進歩が市場を牽引すると予想されます。メーカーやサプライヤーは、細胞膜透過ペプチドのようなペプチドを合成する新しい方法の開発に注力しています。精製プロセスの改善と自動化、廃棄物発生量の低減が、さまざまな用途におけるCPPの需要をさらに高めています。例えば、2022年3月、Creative Peptides社は、CPPs療法を含むペプチド治療薬の開発を加速させる革新的なペプチド創薬サービスを発表しました。

細胞膜透過ペプチドを使用して多くの疾患を治療するための新薬を開発するための資金開拓は、市場関係者に新たな道を開くと予想されます。例えば、2022年9月、Keck Graduate Instituteは、アンジェルマン症候群を標的とするCPPsに関する研究活動を支援するため、Foundation for Angelman Syndrome Therapeuticsから50万米ドルの研究助成金を2年間受け取った。このような取り組みが細胞膜透過ペプチド分野の成長を後押ししています。

しかし、細胞膜透過ペプチドは、確かに手作業で固体支持体上で合成することができるが、これらは面倒で時間がかかります。新しいシステムの設備は、合成規模やソフトウェアによって3万米ドルから20万米ドル以上かかることもあります。したがって、製造装置のコストが高いことが、小規模な企業や新興経済諸国による細胞膜透過ペプチドの開発を妨げる可能性があります。一方、継続的な技術の進歩は、予測期間中にCPPのアプリケーションを後押しする可能性が高いです。

細胞膜透過ペプチド市場レポートハイライト：

  • タイプ別では、薬剤、イメージング剤、核酸などの治療用分子を送達する固有の特性により、合成CPPsセグメントが2023年の市場を独占しました。
  • 用途別では、低毒性と標的細胞への薬物送達効率に起因するドラッグデリバリー分野が2023年に市場の最大セグメントシェアを占めました。
  • 最終用途別では、製薬・バイオテクノロジー企業が2023年の市場をリードしました。これは、製薬・バイオテクノロジー企業において、研究開発活動や新規診断薬・治療薬の生産にペプチドの利用が増加していることに起因しています。
  • 北米は、細胞膜透過ペプチド研究への資金提供の増加、有利な政府政策、技術進歩、同地域における主要事業者の存在により、最高市場シェアで強い地域地位を確立しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因
    • ペプチド合成の技術の進歩
    • 標的ドラッグデリバリーに対する需要の増大
    • 強力なパイプラインの存在
  • 市場抑制要因分析
    • ペプチドの複雑さの増加
    • 製造装置のコストが高い
  • 事業環境分析
    • SWOT分析;要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
    • COVID-19感染症の影響分析

第4章 タイプのビジネス分析

  • 細胞膜透過ペプチド市場：タイプの変動分析
  • タンパク質由来のCPP
  • 合成CPP
  • キメラCPP

第5章 用途のビジネス分析

  • 細胞膜透過ペプチド市場：用途の変動分析
  • ドラッグデリバリー
  • 遺伝子導入
  • 診断
  • 分子イメージング
  • その他

第6章 最終用途のビジネス分析

  • 細胞膜透過ペプチド市場：最終用途の変動分析
  • 製薬およびバイオテクノロジー企業
  • 受託調査機関（CRO）
  • 病院と診療所
  • その他

第7章 地域のビジネス分析

  • 地域別の細胞膜透過ペプチド市場シェア、2023年および2030年
  • 北米
    • 北米の細胞膜透過ペプチド市場、2018年から2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州細胞膜透過ペプチド市場、2018年～2030年
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋地域
    • アジア太平洋細胞膜透過ペプチド市場、2018年から2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカの細胞膜透過ペプチド市場、2018年から2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • MEA細胞膜透過ペプチド市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
    • マーケットリーダー
    • 細胞膜透過ペプチド市場シェア分析、2023年
    • 企業プロファイル
    • 戦略マッピング
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Cell Penetrating Peptide Market, by Region, 2018 - 2030 (USD Million)
  • Table 3 Global Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 5 Global Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 6 North America Cell Penetrating Peptide Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 8 North America Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 9 North America Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 10 U.S. Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 13 Canada Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 15 Canada Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 16 Europe Cell Penetrating Peptide Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 19 Europe Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 20 Germany Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 22 Germany Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 23 UK Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 24 UK Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 25 UK Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 26 France Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 27 France Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 28 France Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 29 Italy Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 31 Italy Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 32 Spain Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 34 Spain Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 35 Denmark Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 37 Denmark Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 38 Sweden Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 40 Sweden Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 41 Norway Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 43 Norway Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Cell Penetrating Peptide Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 48 China Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 49 China Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 China Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 51 Japan Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 Japan Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 54 India Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 55 India Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 56 India Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 57 South Korea Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 South Korea Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 60 Australia Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 Australia Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 63 Thailand Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Thailand Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 66 Latin America Cell Penetrating Peptide Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 69 Latin America Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 70 Brazil Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 72 Brazil Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 73 Mexico Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 75 Mexico Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 78 Argentina Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 85 South Africa Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 89 UAE Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 91 UAE Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Cell Penetrating Peptide Market, by Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Cell Penetrating Peptide Market, by Application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Cell Penetrating Peptide Market, By End-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Cell Penetrating Peptide Market Segmentation
  • Fig. 8 Market Snapshot, 2023
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Cell Penetrating Peptide Market: Disease Type Movement Analysis
  • Fig. 15 Global Cell Penetrating Peptide Market, by Protein-Derived CPPs, 2018 - 2030 (USD Million)
  • Fig. 16 Global Cell Penetrating Peptide Market, by Synthetic CPPs, 2018 - 2030 (USD Million)
  • Fig. 17 Global Cell Penetrating Peptide Market, by Chimeric CPPs, 2018 - 2030 (USD Million)
  • Fig. 18 Global Cell Penetrating Peptide Market: Application Movement Analysis
  • Fig. 19 Global Cell Penetrating Peptide Market, by Drug Delivery, 2018 - 2030 (USD Million)
  • Fig. 20 Global Cell Penetrating Peptide Market, by Gene Delivery 2018 - 2030 (USD Million)
  • Fig. 21 Global Cell Penetrating Peptide Market, by Diagnostics, 2018 - 2030 (USD Million)
  • Fig. 22 Global Cell Penetrating Peptide Market, by Molecular Imaging 2018 - 2030 (USD Million)
  • Fig. 23 Global Cell Penetrating Peptide Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 24 Global Cell Penetrating Peptide Market: End-use Movement Analysis
  • Fig. 25 Global Cell Penetrating Peptide Market, by Pharmaceutical and Biotechnology Company 2018 - 2030 (USD Million)
  • Fig. 26 Global Cell Penetrating Peptide Market, by Contract Research Organization (CROs) 2018 - 2030 (USD Million)
  • Fig. 27 Global Cell Penetrating Peptide Market, by Hospital and Clinics, 2018 - 2030 (USD Million)
  • Fig. 28 Global Cell Penetrating Peptide Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 Regional Outlook, 2023 & 2030
  • Fig. 31 Global Cell Penetrating Peptide Market: Region Movement Analysis
  • Fig. 32 North America Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 34 Canada Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 37 UK Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 38 France Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 39 Italy Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 40 Spain Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 41 Denmark Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 42 Sweden Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 43 Norway Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 44 Asia Pacific Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 45 Japan Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 46 China Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 47 India Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 48 Australia Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 51 Latin America Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 52 Brazil Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 53 Mexico Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 58 UAE Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait Cell Penetrating Peptide Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-167-1

Cell Penetrating Peptide Market Growth & Trends:

The global cell penetrating peptide market size is expected to reach USD 2.85 billion by 2030, expandingat a CAGR of 10.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing demand for targeted drug delivery methods is the primary factor propelling the growth. Technological advancements in chemical modification strategies & peptide synthesis techniques and increasing R&D activities to introduce precise therapeutics are increasing the demand for cell penetrating peptides in the market.

Moreover, rising approvals of novel drugs based on CPP technology is expected to offer lucrative opportunities for the key players during the study period. For instance, in September 2022, Revance Therapeutics, Inc. received U.S. Food and Drug Administration approval for DAXXIFY, which is developed based on cell-penetrating technology for temporary improvement of severe to moderate frown lines. This approval is projected to boost the market growth.

Advancements in the production processes of peptides are expected to drive the market. Manufacturers and suppliers are focused on developing new methods for synthesizing peptides, such as cell penetrating peptides. Improvement and automation of the purification process and lower waste generation are further increasing the demand for CPPs in different applications. For instance, in March 2022, Creative Peptides introduced innovative peptide drug discovery services to speed the development of peptide therapeutics, including CPPs therapies.

Growing funding for developing novel drugs to treat numerous diseases using cell penetrating peptides is anticipated to open new avenues for the market stakeholders. For instance, in September 2022, the Keck Graduate Institute received a research grant of USD 500,000 from the Foundation for Angelman Syndrome Therapeutics for two years to support research activities related to CPPs to targetAngelman Syndrome. Such initiatives are boosting the cell penetrating peptide sector growth.

However, cell penetrating peptides can certainly be synthesized on solid support using manual methods, and these can be tedious and time-intensive. The equipment for new systems can cost from USD 30,000 to USD 200,000 and above, depending on the synthesis scale capability & software. Hence, the high cost of manufacturing equipment may hamper the development of cell penetrating peptides by small players and emerging economies. On the other hand, continuous technological advancements are likely to boost the applications of CPPs during the forecast period.

Cell Penetrating Peptide Market Report Highlights:

  • Based on type, the synthetic CPPs segment dominated the market in 2023 owing to their intrinsic property of delivering therapeutic molecules such as drugs, imaging agents, and nucleic acids
  • Based on application, the drug delivery segment held the largest segment share of the market in 2023, attributable to their low toxicity and efficiency of drug delivery into target cells
  • Based on end-use, the pharmaceutical & biotechnology companies segment led the market in 2023. It can be attributed to the rising utilization of peptides in pharmaceutical and biotechnology companies for R&D activities and the production of novel diagnostics and therapeutics
  • North America has established a strong regional position with a highest market share owing to the increasing funding for cell penetrating peptide research, favorable government policies, technological advancements, and the presence of key operating players in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. List Of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type, Application, and End-use Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Technological Advancements of Peptide Synthesis
    • 3.4.2. Growing Demand for Targeted Drug Delivery
    • 3.4.3. Presence of Strong Pipeline
  • 3.5. Market Restraint Analysis
    • 3.5.1. Increasing Complexity of Peptides
    • 3.5.2. High Cost of Manufacturing Equipment
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Cell Penetrating Peptide market: Type Movement Analysis
  • 4.2. Protein Derived CPPs
    • 4.2.1. Protein Derived CPPs Market, 2018 - 2030 (USD Million)
  • 4.3. Synthetic CPPs
    • 4.3.1. Synthetic CPPs Market, 2018 - 2030 (USD Million)
  • 4.4. Chimeric CPPs
    • 4.4.1. Chimeric CPPs Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Cell Penetrating Peptide Market: Application Movement Analysis
  • 5.2. Drug Delivery
    • 5.2.1. Drug Delivery Market, 2018 - 2030 (USD Million)
  • 5.3. Gene Delivery
    • 5.3.1. Gene Delivery Market, 2018 - 2030 (USD Million)
  • 5.4. Diagnostics
    • 5.4.1. Diagnostics Market, 2018 - 2030 (USD Million)
  • 5.5. Molecular Imaging
    • 5.5.1. Molecular Imaging Market, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-use Business Analysis

  • 6.1. Cell Penetrating Peptide Market: End-use Movement Analysis
  • 6.2. Pharmaceutical and Biotechnology Company
    • 6.2.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 6.3. Contract Research Organizations (CROs)
    • 6.3.1. Contract Research Organizations (CROs) Market, 2018 - 2030 (USD Million)
  • 6.4. Hospitals and Clinics
    • 6.4.1. Hospitals and Clinics Market, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Cell Penetrating Peptide Market Share By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Cell Penetrating Peptide market, 2018 - 2030 (USD MILLION)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. UK Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Mexico Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Reimbursement Scenario
      • 7.5.4.6. Argentina Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Cell Penetrating Peptide market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Cell Penetrating Peptide market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's overview
  • 8.2. Financial performance
  • 8.3. Participant categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Cell Penetrating Peptide market Share Analysis, 2023
    • 8.3.3. Company Profiles
      • 8.3.3.1. Pepscan
      • 8.3.3.1.1. Company Overview
      • 8.3.3.1.2. Financial Performance
      • 8.3.3.1.3. Product Benchmarking
      • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. Creative Peptides
      • 8.3.3.2.1. Company Overview
      • 8.3.3.2.2. Financial Performance
      • 8.3.3.2.3. Product Benchmarking
      • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Cupidpeptides
      • 8.3.3.3.1. Company Overview
      • 8.3.3.3.2. Financial Performance
      • 8.3.3.3.3. Product Benchmarking
      • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. AltaBioscience Ltd
      • 8.3.3.4.1. Company Overview
      • 8.3.3.4.2. Financial Performance
      • 8.3.3.4.3. Product Benchmarking
      • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. AnaSpec
      • 8.3.3.5.1. Company Overview
      • 8.3.3.5.2. Financial Performance
      • 8.3.3.5.3. Product Benchmarking
      • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. Peptomyc
      • 8.3.3.6.1. Company Overview
      • 8.3.3.6.2. Financial Performance
      • 8.3.3.6.3. Product Benchmarking
      • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. BioAlps
      • 8.3.3.7.1. Company Overview
      • 8.3.3.7.2. Financial Performance
      • 8.3.3.7.3. Product Benchmarking
      • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Sarepta Therapeutics, Inc.
      • 8.3.3.8.1. Company Overview
      • 8.3.3.8.2. Financial Performance
      • 8.3.3.8.3. Product Benchmarking
      • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. REVANCE THERAPEUTICS
      • 8.3.3.9.1. Company Overview
      • 8.3.3.9.2. Financial Performance
      • 8.3.3.9.3. Product Benchmarking
      • 8.3.3.9.4. Strategic Initiatives
      • 8.3.3.10. Polypeptide Group
      • 8.3.3.10.1. Company Overview
      • 8.3.3.10.2. Financial Performance
      • 8.3.3.10.3. Product Benchmarking
      • 8.3.3.10.4. Strategic Initiatives
      • 8.3.3.11. Bachem
      • 8.3.3.11.1. Company Overview
      • 8.3.3.11.2. Financial Performance
      • 8.3.3.11.3. Product Benchmarking
      • 8.3.3.11.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others